1 7 5 1 a r t I C l e S Drug addiction has been hypothesized to be driven by two mechanisms: reduction of the activity of the brain reward system 1 and enhanced function of the anti-reward brain stress system 2 , concepts known as within-system and between-systems neuroadaptations, respectively 3 . Prominent downregulation of the mesolimbic dopamine (DA) reward system originating in the ventral tegmental area (VTA) and upregulation of the CRF (also known as corticotropin-releasing hormone, CRH) brain stress system originating in the extended amygdala have been observed in rodents, nonhuman primates and humans during abstinence from drugs of abuse, including tobacco 4,5 .
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The VTA is a critical region for nicotine dependence 6 , and several groups have examined the mechanisms behind DA and CRF neuroadaptations [7] [8] [9] [10] [11] [12] [13] . However, most of these studies were performed in nondependent animals, and these studies postulated that VTA CRF is released from axons that originate in the forebrain and not from local CRF neurons [7] [8] [9] [10] [11] [12] [13] . Thus, how the VTA DA and CRF systems interact in nicotine dependence and withdrawal is essentially unknown. Here we identify in rodents and humans a new population of CRF neurons in the VTA and demonstrate that recruitment of these CRF neurons in the VTA after chronic nicotine contributes to a within-system neuroadaptation of DA neurons to mediate the negative motivational state elicited by nicotine withdrawal.
RESULTS

Nicotine dependence upregulates Crh mRNA in the pVTA
To test whether nicotine dependence upregulates CRF in the brain stress and reward systems, we first measured Crh mRNA in two key regions of the CRF brain stress system, the paraventricular nucleus of the hypothalamus (PVN) and central nucleus of the amygdala (CeA), as well as in the VTA, using quantitative real-time (RT)-PCR. Groups of mice were made nicotine dependent by chronic exposure to nicotine delivered by osmotic minipumps (7 mg per kilogram body weight per day) 14, 15 . Brain punches of the PVN, CeA and VTA (Fig. 1a) were sampled in saline-treated mice, dependent mice with nicotine minipumps or withdrawn mice (8 h after removal of the minipump) 14 . We consistently detected low levels of Crh mRNA in the VTA in saline-treated mice. Crh mRNA levels in the VTA were lower than in the CeA and PVN (VTA ranges 6-14% of CeA and PVN, F 2,33 = 4.9, P = 0.014, Supplementary Fig. 1 ), in accordance with the fact that the CeA and PVN contain large populations of cell bodies that express Crh mRNA, whereas similar neurons have not been reported in the VTA 16 until now. Chronic exposure to nicotine increased Crh mRNA in the VTA in both the dependent and withdrawn groups of mice (F 2,100 = 2.7, P = 0.034), without altering Crh expression in the PVN or CeA (Fig. 1b) . Considering that CRF neurons in the CeA and PVN project to and synapse with both DA and GABA neurons in the VTA 17 and that CRF 1 7 5 2 VOLUME 17 | NUMBER 12 | DECEMBER 2014 nature neurOSCIenCe a r t I C l e S release in the VTA is potentiated after repeated but not acute cocaine exposure 8 , the increase in Crh mRNA in the VTA observed herein could originate from either axonal transport of Crh mRNA to the VTA or the synthesis of Crh mRNA in local VTA neurons.
Identification of CRF neurons in the posterior VTA To test the hypothesis that Crh mRNA is synthesized locally in the VTA, we performed in situ hybridization (ISH) for Crh mRNA in a separate cohort of mice that were drug naive or treated with acute nicotine (1.5 mg kg −1 ), chronic nicotine (7 mg kg −1 d −1 for 12 d), or chronic nicotine and withdrawal (8 h) . A population of CRF neurons with dense Crh mRNA in cell bodies could be detected bilaterally in the VTA in all groups, with most neurons located in the posterior VTA (pVTA), dorsal to the interpeduncular nucleus (IPN) (Fig. 2) . No significant difference in the number of neurons was observed between groups (F 24,180 = 0.82, P = 0.71, Supplementary Fig. 2) , demonstrating that the increase in Crh mRNA was attributable to an increase in the production of Crh in individual neurons and not to an increase in the number of CRF neurons. To confirm the specificity of the Crh mRNA ISH, we performed urocortin (Ucn) mRNA ISH on adjacent sections. Urocortin is a structurally related peptide of the CRF family with affinity for the CRF 2 receptor 18 . No urocortinpositive neurons were observed in the VTA (Supplementary Fig. 3 ), whereas numerous urocortin-positive neurons were observed in the Edinger-Westphal nucleus (Supplementary Fig. 3 ), an area that is known to contain a large population of urocortin neurons 18 . Complementing these results, a recent study demonstrated that nicotine selectively activates DA neurons in the pVTA but not anterior VTA (aVTA), suggesting that CRF-expressing neurons in the pVTA may be dopaminergic 19 . To test this hypothesis, we then examined coexpression in VTA of Crh and tyrosine hydroxylase (TH), a marker for DA neurons in both mice and humans.
Crh mRNA is expressed in DA neurons We performed double labeling for Crh mRNA and DA neurons using Crh mRNA radioactive ISH (Fig. 3a) and fluorescence ISH coupled with TH immunohistochemistry (Fig. 3c,d ) in mice. Crh mRNApositive neurons were located bilaterally in the VTA in TH-enriched regions (Fig. 3b) , and 95.2 ± 4.8% of them expressed TH as well (Fig. 3c,d) . To further confirm the existence of VTA CRF/DA neurons and test their relevance to humans, we performed CRH chromogenic ISH coupled with TH immunohistochemistry in VTA samples from three humans who were nonsmokers without any psychiatric disorders (see Supplementary Table 1 for details). Of 600 CRF neurons, we found that 97.8 ± 0.7% were DA neurons (Fig. 4) , confirming the existence of VTA CRF/DA neurons in both rodents and humans.
Withdrawal-induced CRF peptide depletion in the pVTA and IPN Increased CRF release during drug withdrawal is associated with decreased immunodensity of CRF peptide in neuropils. The decrease in CRF immunodensity reflects CRF depletion from synaptic vesicles subsequent to a local increase in CRF release 20, 21 . We thus used CRF immunohistochemistry to examine whether the recruitment of CRF neurons in the pVTA is also associated with a local decrease in CRF peptide density in neuropils during withdrawal from chronic nicotine. Densitometry revealed that both nicotine dependence and withdrawal from chronic nicotine decreased CRF peptide density as compared with that in saline-treated mice in the pVTA (F 2,31 = 4.40, P = 0.02; Supplementary Fig. 4a ), IPN (F 2,49 = 4.24, P = 0.020; Supplementary Fig. 4d ) and CeA (F 2,67 = 3.15, P = 0.049; Supplementary Fig. 4c ) but not aVTA (F 2,23 = 0.03, P = 0.97; Supplementary Fig. 4a ) or PVN (F 2,21 = 0.75, P = 0.48; Supplementary  Fig. 4b ), demonstrating the specificity of these effects. The combined observations that chronic nicotine exposure increased Crh Crh mRNA levels (∆C t ) in the CeA, VTA and PVN relative to the housekeeping gene Gapdh, normalized to the saline group value in mice chronically exposed to saline (Sal) or nicotine (Nic) or withdrawn from chronic nicotine (WD) as measured by RT-PCR (n = 13 or 14 per group). A significant change in Crh mRNA was observed in the VTA but not CeA or PVN in both the Nic and WD groups (*P < 0.05 versus Sal). Data represent mean + s.e.m. mRNA expression and decreased CRF peptide density in the pVTA and IPN suggest that CRF/DA neurons in the pVTA may release CRF locally in the pVTA and IPN during nicotine dependence. However, the possibility that CRF may also be released from extrinsic projection neurons, such as CRF neurons in the CeA, cannot be ruled out because decreased immunodensity was also observed in the CeA (Supplementary Fig. 4c ). The decreased CRF immunodensity in the CeA replicates results obtained with alcohol-dependent rats 21 and extends this work to nicotine-dependent and nicotinewithdrawn mice.
pVTA Crh mRNA downregulation prevents nicotine dependence-induced dysregulation at GABA neuron-DA neuron synapses The downregulation of VTA DA neuron activity is a key feature of addiction, and recent results have shown that nicotine-induced GABA currents are critical for the phasic activation of dopamine neurons 22 . To test whether Crh mRNA-expressing neurons in the pVTA exert synaptic control over DA neurons, we tested the causal relationship between downregulation of Crh mRNA in the pVTA of nicotine-dependent and nicotine-withdrawn mice and the effect of nicotine on GABAergic currents in DA neurons. Local downregulation of Crh mRNA was performed using an adeno-associated viral vector that encodes a short hairpin RNA targeting Crh mRNA (AAV2-shCRH) or a non-targeting sequence (AAV2-shSCR; Supplementary Fig. 5a,b) . The AAV2-shCRH vector decreased the amount of Crh mRNA by 88.0 ± 6.2% as measured by RT-PCR on VTA punches (t 10 = 11.12, P = 0.0001, n = 6 mice per condition). Some neurons exhibited an even stronger downregulation, having no detectable Crh mRNA remaining after treatment with the silencing vector, such that the total number of CRF-positive neurons decreased by 26% ( Supplementary Fig. 5c,d) .
We first performed whole-cell voltage-clamp recordings of pharmacologically isolated GABA A receptor-mediated spontaneous inhibitory postsynaptic currents (sIPSCs) in putative pVTA DA neurons from naive mice. Dopamine neurons were identified at the time of recording by previously published functional criteria 23, 24 ( Supplementary  Fig. 6 ), and a subset of neurons was collected after recording for Th mRNA expression analysis using single-cell RT-PCR. To examine the effects of nicotine dependence on changes in GABAergic transmission in pVTA DA neurons with and without downregulation of Crh mRNA, neurons infected with either AAV2-shSCR or AAV2-shCRH were identified during withdrawal (6-8 h) by the presence of GFP in the cell body (Fig. 5c) 
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(1 µM) onto pVTA DA neurons produced a transient, significant increase in sIPSC frequency from 1.2 ± 0.2 Hz to 1.9 ± 0.3 Hz (t 7 = 5.048, P = 0.0015, paired t-test; Fig. 5a ,b; 172.9 ± 18.5% of control, t 7 = 3.93, P = 0.0057, one-sample t-test; Fig. 5f ), consistent with previous reports 25, 26 . Nicotine also increased sIPSC frequency in pVTA DA neurons from mice implanted with saline minipumps and infected with AAV2-shSCR or AAV2-shCRH (176.9 ± 18.2% of baseline without nicotine; t 11 = 4.217, P = 0.0014 and 171.5 ± 16.7% of baseline without nicotine; t 11 = 4.248, P = 0.0013, respectively; Fig. 5f ).
In contrast, in pVTA DA neurons from nicotine-dependent mice injected with AAV2-shSCR, acute application of nicotine (1 µM) produced no change in sIPSC frequency (97.7 ± 1.8% of baseline without nicotine; t 10 = 1.228, P = 0.2474; Fig. 7 ). Collectively, these data demonstrate that nicotine-induced activation of GABA neurons, a key mechanism required for DA neuron firing 22 , is deficient in nicotine-dependent mice and that downregulation of Crh mRNA in the VTA can reverse the effect of nicotine dependence. (f) Summary of average change in sIPSC frequency produced by nicotine in pVTA DA neurons from naive mice (n = 8 cells from three mice; *P = 0.01), naive mice injected with either AAV2-shSCR (n = 12 cells from three mice; *P = 0.001) or AAV2-shCRH (n = 12 cells from three mice; *P = 0.001) and nicotine-dependent mice injected with either AAV2-shSCR (n = 11 cells from four mice; P = 0.25) or AAV2-shCRH (n = 10 cells from four mice; *P = 0.001; # P = 0.0003 versus nicotine-dependent AAV2-shSCR). Data represent mean + s.e.m. npg a r t I C l e S pVTA Crh mRNA downregulation prevents the aversive effects of nicotine withdrawal To test whether Crh mRNA-expressing neurons in the pVTA affect the motivational effects of nicotine dependence, we examined the causal relationship between downregulation of Crh mRNA in the pVTA of nicotine-dependent and nicotine-withdrawn mice and the expression of conditioned place aversion to nicotine withdrawal and anxiety-like behavior (Fig. 6a) . In the place-conditioning procedure, a two-way ANOVA revealed a significant interaction between AAV2 injection and nicotine history (F 1,40 = 5.80, P = 0.021; Fig. 6b ). Nicotine-dependent and nicotine-withdrawn mice infused with the AAV2-shSCR control vector in the pVTA showed an aversive motivational response to the withdrawal-paired environment (P = 0.032), which was not observed in mice infused with the AAV2-shCRH vector (P = 0.6392).
Mice that were injected with the AAV2-shCRH vector outside the pVTA (mostly located dorsal or lateral to the pVTA, in the red nucleus or substantia nigra, respectively) showed an aversive response to nicotine withdrawal like that of control mice (unpaired t-test; t 16 = 0.0255, P = 0.798; Supplementary Fig. 8 ), demonstrating the anatomical specificity of this effect. Furthermore, nondependent mice given either the AAV2-shSCR or AAV2-shCRH vector in the pVTA and an acute injection of nicotine (1.75 mg kg -1 ), known to be aversive 14, 15 , showed an aversive response to the nicotine-paired environment (Fig. 6b) , demonstrating that the lack of aversion to withdrawal in dependent mice infused with the silencing vector was not attributable to a general impairment of conditioned place aversion, but was specific to nicotine withdrawal in dependent mice. Taken together, these results suggest that Crh mRNA in the pVTA does not mediate a general aversive response to acute nicotine but specifically mediates aversion to nicotine withdrawal in dependent subjects. These results establish a causal relationship between the recruitment of Crh mRNA-expressing neurons in the pVTA during withdrawal from chronic nicotine and the aversive motivational response to nicotine withdrawal. Activation of the brain CRF-CRF 1 receptor system is associated with increased anxiety-like behavior in humans and animals and is hypothesized to be responsible for the negative emotional state after protracted abstinence 27 . To test this hypothesis, we measured open field activity to evaluate anxiety-like behavior during protracted abstinence (3-4 weeks). Mice injected with the AAV2-shSCR vector spent significantly less time in the central area of the open field than mice injected with the AAV2-shCRH vector (unpaired t-test; t 14 = 2.84, P = 0.013; Fig. 6c ), an effect that was not attributable to a decrease in locomotion (AAV2-shSCR, 2,181 ± 215 cm; AAV2-shCRH, 2,307 ± 146 cm; t 14 = 0.49, P = 0.64). These results demonstrate that upregulation of Crh mRNA in the pVTA is required for the anxiogenic-like effects of protracted nicotine abstinence.
pVTA Crh mRNA downregulation decreases abstinenceinduced escalation of nicotine intake To test whether Crh mRNA-expressing neurons in the pVTA influence the motivation to take nicotine during abstinence, we infused the same AAV2-shCRH or AAV2-shSCR vectors into the pVTAs of rats and measured nicotine self-administration 4 weeks later. In rats given short access (1 h d −1 ) to nicotine self-administration for 10 d, downregulation of Crh mRNA in the VTA did not affect nicotine intake (unpaired t-test; t 17 = 0.59, P = 0.28; Fig. 7 ). We then gave the rats long access (21 h d −1 ) to nicotine self-administration and measured nicotine intake after 7 d of long access and after 48 h of abstinence [27] [28] [29] . Infusion of AAV2-shCRH decreased nicotine intake in long-access rats (unpaired t-test; t 14 = 2.32, P = 0.018) and prevented abstinence-induced increases in nicotine intake, whereas the rats that received AAV2-shSCR showed a significant increase in nicotine intake after 48 h of abstinence (F 1,14 = 4.91, P = 0.044; Fig. 7 ). These results demonstrate that pVTA Crh mRNA downregulation decreases excessive nicotine intake and is particularly effective at decreasing the abstinence-induced escalation of nicotine intake.
Blocking CRF 1 receptors prevents the aversive effect of nicotine withdrawal The present results revealed a depletion of CRF peptide in the pVTA during nicotine withdrawal, hypothesized to reflect a local increase in CRF release 20, 21 . To further test this hypothesis, we examined whether the activation of CRF 1 receptors in the pVTA is necessary for the conditioned aversive motivational response to a withdrawal-paired environment shown by nicotine-dependent and nicotine-withdrawn mice 14, 15 . We administered the CRF 1 
receptor antagonist N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-
2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-amine (MPZP; 20 mg kg −1 , subcutaneously) 27 before place conditioning in nondependent mice given acute nicotine, nicotine-dependent mice with minipumps (7 mg kg −1 d −1 ) or mice in spontaneous withdrawal (8 h) from chronic nicotine (Fig. 8a) . A two-way ANOVA showed a significant effect of systemic MPZP treatment (F 3,103 = 20.51, P < 0.0001; Fig. 8b) . Withdrawn mice pretreated with vehicle showed a conditioned place aversion to a withdrawal-paired environment that was blocked by MPZP (P = 0.0043), demonstrating that activation of CRF 1 receptors during withdrawal is required for the aversive motivational response to nicotine withdrawal. Nicotine-dependent mice that were not in withdrawal and were pretreated with saline showed a conditioned place preference for the nicotine-paired environment that was not blocked by MPZP pretreatment (P = 0.9085). These results suggest that the activation of CRF 1 receptors is not required for the rewarding motivational response to chronic nicotine in dependent mice. Nicotinedependent and nicotine-withdrawn mice pretreated with vehicle (n = 13) showed an aversion to the withdrawal-paired environment that was blocked by pretreatment with the CRF 1 receptor antagonist MPZP (n = 14; *P = 0.0001). Nicotine-dependent mice that were not experiencing withdrawal and were pretreated with vehicle (n = 15) showed a preference for the nicotine-paired environment that was not blocked by MPZP pretreatment (n = 15). Nondependent mice given acute nicotine and pretreated with vehicle (n = 16) showed an aversion to the nicotine-paired environment that was not blocked by MPZP pretreatment (n = 15). Mice with saline minipumps that were pretreated with vehicle (n = 11) or MPZP (n = 12) showed no motivational response to a novel environment or to MPZP. Data represent mean ± s.e.m. (c) Schematic of the aVTA showing placements of the intra-aVTA cannulas (bregma -2.92 mm). (d) Schematic of the pVTA showing placements of the intra-pVTA cannulas (bregma -3.40 mm). (e) Nicotine-dependent and nicotine-withdrawn mice implanted with cannulas in the pVTA that were given vehicle (n = 11) showed an aversive motivational response to the withdrawal-paired environment that was blocked in mice that received intra-pVTA CRF 1 receptor antagonist MPZP (n = 10; *P = 0.0001). Dependent and withdrawn mice implanted with aVTA cannulas that were given vehicle (n = 10) or MPZP (n = 12) showed nicotine withdrawal aversions. Nondependent mice with pVTA cannulas that were pretreated with vehicle (n = 8) or MPZP (n = 10) and acute nicotine showed an aversive motivational response to the nicotine-paired environment. Control mice implanted with saline minipumps and pVTA cannulas that received vehicle (n = 12) or MPZP (n = 11) showed no motivational response to a novel environment or to MPZP. Data represent mean ± s.e.m.
To further evaluate the specificity of this effect, we tested the effect of CRF 1 receptor antagonism on the conditioned avoidance response to an acute aversive dose of nicotine 14 . Nondependent mice given acute nicotine and pretreated with saline showed a conditioned place aversion to the nicotine-paired environment that was not blocked by MPZP pretreatment (P = 0.9228), which was similar to the results obtained using viral vector-mediated Crh mRNA silencing. Mice treated with chronic saline and pretreated with vehicle or MPZP showed no motivational response to a novel environment or to MPZP (P = 0.8697), confirming the specificity of these results. These results demonstrate that activation of CRF 1 receptors is selectively required to mediate the aversive motivational response to nicotine withdrawal in dependent mice but not the aversive (in nondependent mice) or rewarding (in dependent mice) motivational effects of nicotine.
To test whether activation of CRF 1 receptors specifically in the pVTA mediates the conditioned aversive motivational response to nicotine withdrawal, we measured place conditioning in separate groups of mice after infusion, before conditioning, of MPZP (0.14 ng/0.3 µl) or vehicle in the aVTA (Fig. 8c) and pVTA (Fig. 8d) . A two-way ANOVA revealed a significant interaction between treatment and nicotine history (F 3,76 = 3.351, P = 0.0233; Fig. 8e) . Nicotine-dependent mice that were in withdrawal and pretreated with vehicle showed an aversive response to the withdrawal-paired environment that was blocked in withdrawn mice pretreated with intra-pVTA MPZP (P = 0.0063). However, the ability of MPZP to block nicotine withdrawal aversions was not observed when the CRF antagonist was infused into the aVTA (P = 0.7108). These results demonstrate that CRF 1 receptor activation specifically in the pVTA is necessary for the acquisition of the aversive motivational response to nicotine withdrawal in dependent mice. Like mice that received systemic MPZP or the AAV2-shCRH, mice in a nondependent motivational state that received intra-pVTA MPZP or vehicle before acute nicotine administration showed a conditioned avoidance to the acute nicotine-paired environment (P = 0.7323). Intra-VTA MPZP had no motivational effects on its own, such that mice implanted with saline minipumps showed neither a preference nor aversion to a MPZP-paired environment (P = 0.8996).
DISCUSSION
This report identifies a population of DA neurons in the VTA that expresses CRF in both rodents and humans. Chronic exposure to nicotine increased Crh mRNA in the pVTA, and this was associated with a depletion of CRF peptide in VTA and IPN neuropils and blocked nicotine-induced activation of GABAergic input onto DA neurons. Downregulation of Crh mRNA in the pVTA restored GABAergic control over DA neurons and prevented the motivational effects of nicotine withdrawal as measured by conditioned place aversion, anxiety-like behavior and escalated nicotine self-administration. Pharmacological testing further demonstrated that the motivational effects of nicotine withdrawal were mediated by activation of CRF 1 receptors in the pVTA.
The detection of CRF neurons in the brain can be very challenging. To confirm the existence of this population of CRF neurons in the VTA, we used a variety of complementary approaches: RT-PCR, radioactive and chromogenic ISH, immunohistochemistry, and fluorescence ISH combined with immunohistochemistry. These techniques revealed direct evidence of CRF neurons in the VTA in rodents and humans. To further confirm the existence of CRF neurons in the VTA, we used several controls, including RT-PCR of housekeeping genes, CRF immunodensity in the aVTA and ISH for urocortin, a member of the CRF family that is structurally related to CRF. Confirming the specificity of the present results, housekeeping genes were not upregulated, CRF immunodensity was altered in the pVTA and IPN but not aVTA, and urocortin-positive neurons were not observed in the pVTA.
TH immunohistochemistry combined with CRH ISH showed that most CRF-positive neurons (95% in mice and 98% in humans) also expressed TH, a marker of DA neurons. CRF neurons were distributed bilaterally in the VTA, with the highest number observed in the pVTA in the region dorsal to the IPN. The increase in Crh mRNA in nicotine-relative to saline-treated mice was associated with the depletion of CRF in IPN and pVTA neuropils (but not aVTA), suggesting These results suggest that VTA CRF neurons may release CRF through axons in the IPN and through both axons and dendrites in the pVTA to act as autocrine and paracrine signals 30 . Indeed, unlike classic neurotransmitters, neuropeptides are not only found in axons but also found abundantly in dendrites 31 . CRF specifically is found in dendrites associated with endomembranes and large dense-core vesicles 32 , and CRF immunoreactivity has been observed both in axon terminals and dendrites in the VTA 17 . Many groups have attempted to measure CRF in the VTA in rats but failed because of the low concentration, high degradation rate, and low stability and recovery of CRF using microdialysis. The only report of CRF microdialysis in the VTA has not been replicated, and it involved intense footshock stress 33 . New techniques are attempting to use cell-based neurotransmitter fluorescent engineered reporters to reliably measure physiological CRF levels, but these methods are still in their initial stages of development.
The decreased CRF immunodensity in the CeA is in accordance with previous reports showing increased CRF release 27 and reduction of negative emotional states after blockade of CRF 1 receptors in the CeA 34 . The lack of increased Crh mRNA in the CeA suggests that the VTA and CeA CRF neurons may be upregulated at different time points. Recent reports showing increased Crh mRNA in the CeA 16-24 h into withdrawal 35, 36 may explain why an increase was not observed 8 h into withdrawal in the present study. Taken together, these studies demonstrate that blocking the CRF-CRF 1 system in the CeA or VTA is sufficient to prevent the negative emotional states of nicotine withdrawal.
In addition to the upregulation of Crh mRNA in VTA DA neurons, chronic nicotine dysregulated GABA-DA synapses, as demonstrated by the loss of inhibitory responses (sIPSCs) to acute nicotine in VTA DA neurons in dependent mice. Virally mediated downregulation of Crh mRNA in the pVTA abolished the effect of chronic nicotine on GABA-DA synapses and prevented the motivational effect of withdrawal as measured by conditioned place aversion, anxiety-like behavior, and escalated nicotine self-administration after abstinence. These findings may explain why nicotine dependence in vivo decreases in tonic dopaminergic activity in the VTA 15 and DA release in the nucleus accumbens 37 , whereas acute CRF 1 receptor antagonism increases tonic DA activity 38 . These findings also may provide a mechanism for observed decreases in accumbal DA release in response to rewards after CRF administration in the VTA 9 , the decreased phasic dopamine release observed in cocaine-dependent rats 39 and the decreased prefrontal dopamine metabolism after intra-VTA CRF administration 40 . Indeed, while pharmacological and optogenetic activation of VTA GABA neurons produces robust inhibition of DA neurons 41, 42 , transient physiological activation of GABAergic input onto DA neurons is required for DA firing 22 because transient GABAergic inputs promote rebound firing in DA neurons. Taken together, these results demonstrate that the activation of a CRF-CRF 1 system in the pVTA may dysregulate transient GABAergic inputs that are critical for dopaminergic firing. Similar effects of CRF on GABAergic input have been observed in the CeA 43 .
Increasing evidence suggests that a neurobiological switch occurs in the VTA during the transition from nondependent to drug-dependent motivational states 15, [44] [45] [46] , suggesting that the effect of CRF 1 receptor activation in dependent versus nondependent animals may be opposite. Our results showed a specific role for CRF in the pVTA in mediating the aversive response to nicotine withdrawal in dependent mice but not to acute nicotine in nondependent mice. The specific effect on nicotine intake in long-access but not short-access rats is consistent with this hypothesis, demonstrating that the recruitment of VTA CRF/DA neurons contributes to the development of nicotine dependence. The present results do not exclude the possibility that the expression of CRF in DA neurons alters plasticity in non-DA neurons and circuits in the VTA that may also alter DA function and have motivational significance 46, 47 . However, taken with previous results demonstrating that nicotine withdrawal is signaled by a specific pattern of tonic VTA dopaminergic activity 15 and that activation of CRF 1 receptors can mediate changes in VTA DA neuron population activity 38 , the present results suggest that chronic nicotine leads to an upregulation of CRF in pVTA DA neurons that is released onto VTA CRF 1 receptors to mediate the aversive motivational effects of nicotine withdrawal. Future studies are necessary to directly test this hypothesis for nicotine and other drugs of abuse.
The transition to drug dependence and drug addiction has been hypothesized to be driven and maintained by two relatively independent systems: downregulation of DA function in the VTA, a withinsystem neuroadaptation that leads to a reward deficit disorder 48 , and upregulation of CRF function, a between-systems neuroadaptation that leads to a stress surfeit disorder 49 . Here we identify a population of CRF neurons in the core of the brain incentive salience and reward system in DA neurons of the pVTA, and show that upregulation of Crh mRNA and activation of CRF 1 receptors locally in the pVTA occur after the induction of nicotine dependence and are required for the aversive motivational effects of nicotine withdrawal. This withinsystem neuroadaptation links the brain reward and stress systems in the same neurobiological substrate, providing evidence that DA and CRF interact in the VTA to mediate the aversive motivational effects of nicotine withdrawal during dependence.
METHODS
Methods and any associated references are available in the online version of the paper. ML, ± 0.7 mm; DV, −8.2 mm. Each mouse received 0.75 µl/side and each rat received 1 µl/side of either the AAV2-shCRH or AAV2-shSCR at an infusion rate of 0.1 µl/min using injectors that protruded 1 mm beyond the cannula (for mice) or 2 mm beyond the cannula (for rats). The injectors were left in place for 10 more minutes to ensure adequate diffusion of the solution. Infusions were delivered via polyethylene tubing (PE 20) that was connected to a Hamilton 10-µl syringe.
For intra-VTA MPZP infusion, dummy cannulas were secured in the injection cannulas by dust caps, and the animals were allowed to recover for 1 week before drug infusion and conditioning. On conditioning days, the dust cap and dummy cannulas were removed and replaced with injector cannulas. Mice were lightly restrained and infused with 0.14 µg in 0.3 µl MPZP or 20% HBC (control solution) over 1 min. After the behavioral experiments were completed, the mice were sacrificed and perfused, and cannula placement was verified by cresyl violet staining. Sixteen of 100 mice were excluded owing to incorrect cannula placements.
Real-time RT-PcR. RNA was isolated using a Qiagen RNeasy extraction kit with DNase to remove genomic DNA contamination and a specified amount of RNA was reverse-transcribed using SuperScript III (Invitrogen, Foster City, CA, USA) to generate cDNAs. Quantitative real-time PCR was performed using Taqman Gene Expression Assays for Crh (Mm01293920_s1) in a 7900HT Fast RT-PCR System (both from Life Technologies, Carlsbad, CA, USA). Quantification was performed using the ∆C t method with Gapdh as an endogenous control. For single-cell RT-PCR analysis, single cells were collected from AAV2-shCRHor AAV2-shSCR-injected brain slices by aspiration of neuronal cytoplasm immediately after electrophysiological recordings, and processed with the Picopure RNA isolation kit (Life Technologies, Carlsbad, CA, USA) for RNA isolation and reverse transcription (RT) using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The cDNA obtained from single neurons was subjected to preamplification for 20 cycles, followed by real-time RT-PCR to detect the expression of TH with forward (5′-ACTGCTTCTCAACCACATCTT-3′) and reverse (5′-GGGTAGAATACAGCATGAAGGG-3′) primers using the SSO Advanced SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) according to manufacturer's protocol.
Radioactive in situ hybridization. Mice were anesthetized with chloral hydrate (350 mg kg −1 , i.p.) and perfused via the ascending aorta with 0.9% saline followed by ice-cold 4% paraformaldehyde in 0.1 M borate buffer, pH 9.5. The brains were removed, postfixed for 3 h, and cryoprotected in 20% sucrose in 0.1 M phosphate buffer overnight at 4 °C. Five one-in-four series of 30-µm-thick frozen coronal sections were cut, collected, and stored in 30% ethylene glycol and 20% glycerol in 0.1 M phosphate buffer at −20 °C until processing. In situ hybridization was performed using 35 S-labeled sense (control) and antisense cRNA probes labeled to similar specific activities using a full-length (1.2 kb) probe for the mRNA that encodes CRF (1.2 kb; K. Mayo, Northwestern University, Evanston, IL, USA). Sections were mounted on Superfrost Plus slides and dried under vacuum overnight. They were postfixed with 10% formalin for 30 min at room temperature, digested with 10 µg/ml proteinase K for 15 min at 37 °C and acetylated for 10 min. The probes were labeled to specific activities of 1 × 10 9 -3 × 10 9 c.p.m./µg and applied to the slides at concentrations of ~10 7 c.p.m./ml overnight at 56 °C in a solution that contained 50% formamide, 0.3 M NaCl, 10 mM Tris, 1 mM EDTA, 0.05% tRNA, 10 mM dithiothreitol, 1× Denhardt's solution and 10% dextran sulfate, after which they were treated with 20 µg/ml of RNase A for 30 min at 37 °C and washed in 15 mM NaCl/1.5 mM sodium citrate with 50% formamide at 70 °C. The slides were then dehydrated and exposed to X-ray film (Kodak Biomax MR, Eastman Kodak, Rochester, NY, USA) for 18 h. They were coated with Kodak NTB-2 liquid emulsion and exposed at 4 °C for 3-4 weeks as determined by the strength of the signal on the film. The slides were developed with Kodak D-19 and fixed with Kodak rapid fixer. One series of sections that adjoined those used for analysis was stained with thionin to facilitate the accurate localization of hybridization signals. The experimenters were blind to the experimental history of the animals.
densitometry.
The semiquantitative densitometric analysis of hybridization signals for Crh mRNA was performed on emulsion-dipped slides. Photomicrographs were captured using a Leica light microscope with a Hamamatsu Orca chargecoupled-device camera through OpenLab software (version 3.1.5) and analyzed using ImageJ software. The optical densities of hybridization signals were determined under dark-field illumination at 400× magnification with a circular region of interest (ROI) of 20 µm diameter that was placed over individual neurons. The size of the ROI was chosen on the basis of the average diameter of THimmunoreactive neurons in the pVTA. The sections were analyzed at regular 120-µm intervals across the pVTA. Optical densities were corrected for the average background signal that was determined by sampling 20 cell-sized areas per section in nonsignal areas adjacent to the pVTA. Optical density values are expressed in gray scale values of 1 to 256, corresponding to a gradation from low to high absorbance, respectively. Neurons on both sides of the brain were pooled for analysis to calculate the animal mean. Animal means were then grouped according to virus treatment, averaged and statistically analyzed. The experimenters were blind to the experimental history of the animals during densitometry analysis.
Immunohistochemistry. Mice were anesthetized with 3% halothane, preperfused transcardially with a solution of 0.5 ml heparin/100 ml saline for
